Please login to the form below

Not currently logged in
Email:
Password:

Counterfeit medicines summit in US

Anti-counterfeiting group, the Partnership for Safe Medicines has announced it will hold its inaugural conference in October in Washington, DC

The Partnership for Safe Medicines, a coalition devoted to combating the counterfeiting of prescription drugs, has announced that it will hold its inaugural conference in October in Washington, DC.

The coalition is made up of dozens of organisations and associations, including Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organisation, the World Health Organisation (WHO), pharmacists' groups, patient organisations, and veterans' groups, among others. Sponsors of the first annual conference include Pfizer, Merck, Eli Lilly and Novartis.

The conference, which takes place at the National Press Club on October 8, will bring together leaders in academia, government and industry to explore strategies and policy recommendations aimed at combating counterfeiting.

The day will be divided into three main discussions: one on who is being harmed by counterfeiting, one on who is profiting by counterfeiting, and one on what progress has been made this year against counterfeiting. Moderators will include Dr Mary Shephard, director of the Centre for Pharmacoeconomic Studies at the University of Texas-Austin; Dr Bryan Liang, executive director of the Institute of Health Law Studies at California Western School of Law; and Tom Kubic, president of the Pharmaceutical Security Institute.

29th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....